Home/Pipeline/FILSPARI (sparsentan)

FILSPARI (sparsentan)

IgA Nephropathy (IgAN)

ApprovedCommercial

Key Facts

Indication

IgA Nephropathy (IgAN)

Phase

Approved

Status

Commercial

Company

Travere Therapeutics

About Travere Therapeutics

Travere Therapeutics is a San Diego-based biopharma leader dedicated to rare diseases, particularly in nephrology and metabolism. The company has successfully transitioned to commercial operations with a fully approved therapy for IgA nephropathy (IgAN) and a late-stage pipeline targeting conditions like focal segmental glomerulosclerosis (FSGS) and classical homocystinuria (HCU). Its strategy leverages deep community engagement and scientific expertise to navigate complex development pathways and establish new standards of care in niche markets.

View full company profile

Therapeutic Areas

Rare Kidney Diseases Rare Metabolic Disorders

Other IgA Nephropathy (IgAN) Drugs

Drug	Company	Phase	Status
R1065	Harbour BioMed	Discovery	Active (Global)
TARPEYO (Nefecon)	Calliditas Therapeutics	Approved	Commercial
TARPEYO (Nefecon) OLE	Calliditas Therapeutics	Phase 3	Active (Open-label Extension)
KP104	Kira Pharmaceuticals	Phase 2	Active
IFX-301	Infinimmune	Preclinical	Active
Atacicept	Vera Therapeutics	Phase 2b/3	Primary endpoint met in Phase 3 (ORIGIN 3) in June 2025
Telitacicept	Vor Biopharma	BLA Submitted	Filed in China